SEC Contract Filing

Filing Date: 2024-03-13

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm247944d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Exhibit&nbsp;10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-variant: small-caps"><B><I>Execution
Version</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps"><B>EMPLOYMENT
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Employment Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is made as of February&nbsp;29, 2024 (the &ldquo;<U>Effective Date</U>&rdquo;) by and between Voyager
Therapeutics,&nbsp;Inc. (the &ldquo;<U>Company</U>&rdquo;) and Toby Ferguson, M.D., Ph.D. (the &ldquo;<U>Executive</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Employment</U></FONT></B><FONT STYLE="font-size: 10pt">.
The Company and the Executive desire that the Executive be employed as the Company&rsquo;s Chief Medical Officer. The employment relationship
between the Company and the Executive shall be governed by this Agreement, with the Executive&rsquo;s first day of employment commencing
as of a date mutually agreed upon by the Company and the Executive, but in no event later than March&nbsp;25, 2024 (the &ldquo;<U>Commencement
Date</U>&rdquo;), and continuing in effect until terminated by either party in accordance with this Agreement. At all times, the Executive&rsquo;s
employment with the Company will be &ldquo;at-will,&rdquo; meaning that the Executive&rsquo;s employment may be terminated by the Company
or the Executive at any time and for any reason, subject to the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Position,
Reporting and Duties</U>. </FONT></B><FONT STYLE="font-size: 10pt"> The Executive will serve as the Company&rsquo;s Chief Medical Officer,
reporting to the Company&rsquo;s President&nbsp;&amp; Chief Executive Officer (&ldquo;<U>CEO</U>&rdquo;). The Executive agrees to abide
by the rules, regulations, instructions, personnel practices and policies of the Company and any changes therein that may be adopted from
time to time by the Company. The Executive&rsquo;s normal place of work will be in the Company&rsquo;s Lexington, Massachusetts offices,
unless the Executive is traveling on behalf of the Company. The Executive shall devote the Executive&rsquo;s full working time and efforts
to the business and affairs of the Company and shall not engage in any other business activities without the prior written approval of
the CEO and provided that such activities do not create a conflict of interest or otherwise interfere with the Executive&rsquo;s performance
of the Executive&rsquo;s duties to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compensation
and Related Matters</U></FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Base
Salary</U>. The Executive will receive a base salary at the annual rate of $485,000 (&ldquo;<U>Base Salary</U>&rdquo;), which Base Salary
is subject to review and redetermination by the Company from time to time. The Base Salary will be payable in a manner that is consistent
with the Company&rsquo;s usual payroll practices for senior executives. The Executive shall be eligible to participate in the annual salary
review for the 2025 calendar year and in the annual salary review for each subsequent year thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Annual
Bonus</U>. The Executive will be eligible to participate in the Company&rsquo;s Senior Executive Cash Incentive Bonus Plan (the &ldquo;<U>Incentive
Bonus Plan</U>&rdquo;), as approved by the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;), its Compensation Committee,
or any other committee of the Board from time to time, commencing for calendar year 2024. T